BAC vs MRVI Stock Comparison
BAC currently leads MRVI in this stock comparison, with AIQ scores of 47 vs 46. The clearest difference is value, while MRVI has the stronger momentum profile.
What is the main difference between BAC and MRVI?
BAC leads the current stock comparison as Bank of America Corporation, with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Bank of America Corporation vs Maravai LifeSciences Holdings, Inc.
BAC leads
BAC leads by 1 AIQ points, primarily on Value and Quality, having only recently taken the lead back from MRVI.
Fragile: 4 of 6 evidence groups support BAC, the lead recently changed hands, and its signal state is cleanly positive.
Bank of America Corporation
Maravai LifeSciences Holdings, Inc.
The Algovestiq AIQ Score currently favors BAC over MRVI, 47 versus 46 as of Oct 31, 2026. BAC's advantage is driven primarily by stronger value and quality, while MRVI holds the stronger momentum profile. BAC also shows the weaker technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor BAC today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 1 points. BAC lead: Reversed — MRVI led by 2 AIQ points 30 sessions ago; BAC now leads by 1.
Compare Bank of America Corporation and Maravai LifeSciences Holdings, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare BAC and MRVI against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum26 vs 74MRVI +48
- Value57 vs 34BAC +23
- Quality49 vs 33BAC +16
- Risk Resilience60 vs 46BAC +14
4 of 6 evidence groups favor BAC. BAC’s edge is concentrated in value and quality; MRVI keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-10-28, compared against the prior scored session 2026-10-27.
Largest factor move: Risk Resilience +1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 3 active signals are unchanged.
Largest factor move: Momentum +5
New signals
- Keltner Channel Breakout — bullish, volatility, short horizon
BAC's lead narrowed by 2 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — BAC and MRVI both carry a full feed there.
The central trade-off
BAC (Bank of America Corporation): the stronger current systematic profile, led by value and quality.
MRVI (Maravai LifeSciences Holdings, Inc.): the counter-case, on momentum, technicals — but at materially higher volatility, 86% against 20.8%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
BACBAC on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
BACBAC on combined revenue and EPS growth.
Value
BACBAC on the peer-relative Value factor, by 23 points.
Momentum
MRVIMRVI on the Momentum factor, by 48 points.
Lower downside
BACBAC on Risk Resilience, by 14 points.
Analyst upside
BACBAC on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | BAC | MRVI | Note |
|---|---|---|---|
| Implied upside to target | +32.5% | -10.4% | BAC has more room |
| Target dispersion | +22.6% | +28.6% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 11 | 2 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor BAC. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 47 vs 46 |
| Fundamentals | BACon balance | revenue growth -3.3% vs -21.9%; EPS growth -23.8% vs -213.7%; TTM ROE 10.7% vs -35.4%; gross margin 60.4% vs 34.6%; operating margin 22.4% vs 46% — BAC takes 4 of 5 decided legs, not all of them |
| Valuation | BAC | Value 57 vs 34 |
| Technicals | MRVI | Price vs 50-day -12.1% vs 4.4%; vs 200-day -7.5% vs 63.7% |
| Risk Resilience | BAC | Risk Resilience 60 vs 46 |
| Analyst expectations | BAC | Target upside 32.5% vs -10.4% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BAC and MRVI and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 1 points. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BAC.
How the comparison changed
120 daily snapshots · Jun 29 – Oct 28BAC lead: Reversed — MRVI led by 2 AIQ points 30 sessions ago; BAC now leads by 1.
- Today
- BAC +1
- 47 vs 46
- 7 sessions ago
- BAC +11
- 47 vs 36
- 30 sessions ago
- MRVI +2
- 41 vs 43
- 90 sessions ago
- BAC +3
- 50 vs 47
The lead changed hands 2 times in this window, most recently on Oct 12 when BAC moved ahead of MRVI.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 0 bearish / 1 neutral
No signal that the other name lacks.
5 bullish / 0 bearish / 2 neutral
Only MRVI
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (5.68%)
- Keltner Channel Breakout — bullish, volatility, short horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Uptrend Structure Active — bullish, trend, long horizon
Both carry 3 more signals that do not separate them: Bollinger Band Squeeze, Golden Cross Active, MACD Bullish Crossover.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -2.21%, AIQ 0 points).
Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -7.68%, AIQ +2 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1MRVI closes the Value gap — currently 23 points behind, the largest single contributor to BAC's edge.
- 2MRVI's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend.
- 3BAC's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
BAC leads on balance| Metric | BAC | MRVI |
|---|---|---|
| Revenue growth (YoY) | -3.3% | -21.9% |
| EPS growth (YoY) | -23.8% | -213.7% |
| Gross margin | 60.4% | 34.6% |
| Operating margin | 22.4% | 46% |
| Return on equity (TTM) | 10.7% | -35.4% |
| Debt to equity | 1.28 | 0.86 |
Performance
MRVI leads 6 of 6 windows| Metric | BAC | MRVI |
|---|---|---|
| 1 week (5 sessions) | 0.1% | 12.3% |
| 1 month (20 sessions) | -6.6% | 11% |
| 3 months (63 sessions) | -17.6% | 25.9% |
| 6 months (126 sessions) | -3.8% | 144.3% |
| Year to date | -7.5% | 161.5% |
| 1 year (252 sessions) | -3.3% | 149.3% |
Technicals
MRVI has the stronger structure| Metric | BAC | MRVI |
|---|---|---|
| RSI (14) | 31.2 | 63.8 |
| ADX (14) | 49.4 | 15.6 |
| Price vs 50-day | -12.1% | 4.4% |
| Price vs 200-day | -7.5% | 63.7% |
| Volatility (1M, annualized) | 20.8% | 86% |
Risk
BAC is the more resilient| Metric | BAC | MRVI |
|---|---|---|
| Beta | 0.73 | 1.47 |
| Sharpe ratio | -0.25 | 1.68 |
| Sortino ratio | -0.32 | 3.27 |
| Max drawdown | -22.3% | -29.6% |
| Current drawdown | -21.5% | -5.6% |
| Annualized volatility | 21.8% | 69.3% |
| Value at risk (95%) | -2.5% | -6.3% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, BAC or MRVI?
On the Algovestiq AIQ Score, BAC is the stronger of the two as of Oct 31, 2026, scoring 47 against MRVI's 46. The edge comes from value and quality. MRVI is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is BAC or MRVI the better buy right now?
BAC carries the stronger systematic profile as of Oct 31, 2026, and the comparison is rated Fragile — 4 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 1 points. Treat the lead as provisional.
Why does the AIQ Score favor BAC over MRVI?
The composite weights Quality, Value, Momentum and Risk Resilience. MRVI leads Momentum by 48 points; BAC leads Value by 23 points; BAC leads Quality by 16 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, BAC or MRVI?
Analyst price targets imply +32.5% upside for BAC and -10.4% for MRVI, so the Street currently favors BAC. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, BAC or MRVI?
BAC is the better-valued of the two on the peer-relative Value factor. BAC on the peer-relative Value factor, by 23 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, BAC or MRVI?
BAC on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, BAC or MRVI?
MRVI on the Momentum factor, by 48 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, BAC or MRVI?
BAC is the more resilient of the two, so the other name carries the higher downside risk. BAC on Risk Resilience, by 14 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is BAC more profitable than MRVI?
The profitability evidence is mixed: gross margin 60.4% vs 34.6%; operating margin 22.4% vs 46%; ttm roe 10.7% vs -35.4%. BAC leads on two measures and MRVI on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is BAC's lead over MRVI getting stronger or weaker?
BAC lead: Reversed — MRVI led by 2 AIQ points 30 sessions ago; BAC now leads by 1. This is measured from 120 daily comparison snapshots between 2026-06-29 and 2026-10-28. The lead has changed hands 2 times in that window, most recently on 2026-10-12, when BAC moved ahead of MRVI.
What would change the BAC vs MRVI verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: MRVI closes the Value gap — currently 23 points behind, the largest single contributor to BAC's edge; MRVI's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend; BAC's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about BAC and MRVI?
BAC: 2 bullish / 0 bearish / 1 neutral. MRVI: 5 bullish / 0 bearish / 2 neutral. The most decision-relevant rule on BAC is Golden Cross Active (bullish, long horizon). On MRVI it is Golden Cross Active (bullish, long horizon).
Compare BAC and MRVI with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.